Abbott Laboratories ABT
We take great care to ensure that the data presented and summarized in this overview for ABBOTT LABORATORIES is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABT
View all-
Vanguard Group Inc Valley Forge, PA169MShares$22.4 Billion0.34% of portfolio
-
Black Rock Inc. New York, NY131MShares$17.4 Billion0.31% of portfolio
-
State Street Corp Boston, MA77.2MShares$10.2 Billion0.35% of portfolio
-
Capital International Investors Los Angeles, CA68MShares$9.02 Billion1.51% of portfolio
-
Capital Research Global Investors Los Angeles, CA54.1MShares$7.18 Billion1.31% of portfolio
-
Morgan Stanley New York, NY36.1MShares$4.79 Billion0.29% of portfolio
-
Geode Capital Management, LLC Boston, MA35.7MShares$4.73 Billion0.32% of portfolio
-
Jpmorgan Chase & CO New York, NY35.2MShares$4.67 Billion0.32% of portfolio
-
Northern Trust Corp Chicago, IL22.1MShares$2.93 Billion0.36% of portfolio
-
Norges Bank Oslo, Q821MShares$2.78 Billion0.32% of portfolio
Latest Institutional Activity in ABT
Top Purchases
Top Sells
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Insider Transactions at ABT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 07
2025
|
Lisa D Earnhardt EVP AND GROUP PRESIDENT |
SELL
Open market or private sale
|
Direct |
200
-0.28%
|
$27,200
$136.65 P/Share
|
Mar 07
2025
|
Lisa D Earnhardt EVP AND GROUP PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.28%
|
$16,000
$80.98 P/Share
|
Mar 06
2025
|
Lisa D Earnhardt EVP AND GROUP PRESIDENT |
SELL
Open market or private sale
|
Direct |
91,167
-55.9%
|
$12,125,211
$133.82 P/Share
|
Mar 06
2025
|
Lisa D Earnhardt EVP AND GROUP PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
91,167
+35.86%
|
$7,293,360
$80.98 P/Share
|
Mar 03
2025
|
Andrea F Wainer RETIRED EVP |
SELL
Open market or private sale
|
Direct |
949
-1.26%
|
$130,962
$138.17 P/Share
|
Mar 03
2025
|
Eric Shroff Senior Vice President |
SELL
Open market or private sale
|
Direct |
562
-1.73%
|
$77,556
$138.17 P/Share
|
Mar 03
2025
|
Louis H. Morrone EXECUTIVE VICE PRESIDENT |
SELL
Open market or private sale
|
Direct |
1,111
-1.63%
|
$153,318
$138.17 P/Share
|
Mar 03
2025
|
Mary K Moreland EXECUTIVE VICE PRESIDENT |
SELL
Open market or private sale
|
Direct |
791
-0.82%
|
$109,158
$138.17 P/Share
|
Mar 03
2025
|
John A. Mccoy Jr. VICE PRESIDENT AND CONTROLLER |
SELL
Open market or private sale
|
Direct |
562
-2.6%
|
$77,556
$138.17 P/Share
|
Feb 28
2025
|
Andrea F Wainer RETIRED EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
7,313
-8.85%
|
$987,255
$135.87 P/Share
|
Feb 28
2025
|
Daniel Gesua Sive Salvadori EVP AND GROUP PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
8,462
-5.95%
|
$1,142,370
$135.87 P/Share
|
Feb 28
2025
|
Louis H. Morrone EXECUTIVE VICE PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
4,386
-6.06%
|
$592,110
$135.87 P/Share
|
Feb 28
2025
|
Mary K Moreland EXECUTIVE VICE PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
5,598
-5.49%
|
$755,730
$135.87 P/Share
|
Feb 28
2025
|
John A. Mccoy Jr. VICE PRESIDENT AND CONTROLLER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,096
-4.82%
|
$147,960
$135.87 P/Share
|
Feb 28
2025
|
Robert B Ford CHAIRMAN AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,651
-11.11%
|
$4,272,885
$135.87 P/Share
|
Feb 28
2025
|
Lisa D Earnhardt EVP AND GROUP PRESIDENT |
SELL
Payment of exercise price or tax liability
|
Direct |
8,322
-10.37%
|
$1,123,470
$135.87 P/Share
|
Feb 28
2025
|
Philip P Boudreau EVP AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,908
-7.99%
|
$662,580
$135.87 P/Share
|
Feb 28
2025
|
Hubert L Allen EXECUTIVE VICE PRESIDENT, GC |
SELL
Payment of exercise price or tax liability
|
Direct |
8,382
-4.19%
|
$1,131,570
$135.87 P/Share
|
Feb 25
2025
|
Andrea F Wainer RETIRED EVP |
BUY
Grant, award, or other acquisition
|
Direct |
12,278
+12.94%
|
-
|
Feb 25
2025
|
Daniel Gesua Sive Salvadori EVP AND GROUP PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
16,534
+10.41%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 196K shares |
---|---|
Exercise of conversion of derivative security | 900K shares |
Payment of exercise price or tax liability | 81.4K shares |
---|---|
Open market or private sale | 929K shares |